Is RENAL IMPAIRMENT a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed RENAL IMPAIRMENT.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 22 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported RENAL IMPAIRMENT to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and RENAL IMPAIRMENT. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause RENAL IMPAIRMENT, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes RENAL IMPAIRMENT. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if RENAL IMPAIRMENT ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing RENAL IMPAIRMENT: 22
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where RENAL IMPAIRMENT is a reported side effect: 0.6609%

FDA reports of any drug causing RENAL IMPAIRMENT : 24428
Average percentage for all medicated patients where RENAL IMPAIRMENT is reported as a complication: 0.1531%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
DESMOID TUMOUR ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
ANGINA PECTORIS ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
SARCOMA ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with RENAL IMPAIRMENT:

TRASYLOL (8255 patients)
LASIX (2660 patients)
HEPARIN (2202 patients)
ASPIRIN (1995 patients)
PREDNISOLONE (1737 patients)
FUROSEMIDE (1309 patients)
NEORAL (1197 patients)
PROTAMINE SULFATE (1127 patients)
NITROGLYCERIN (1112 patients)
LIPITOR (1088 patients)
RED BLOOD CELLS (1067 patients)
VANCOMYCIN (1000 patients)
ACETYLSALICYLIC ACID SRT (996 patients)
ALLOPURINOL (974 patients)
LISINOPRIL (957 patients)
NORVASC (927 patients)
CYCLOSPORINE (848 patients)
INSULIN (825 patients)
FENTANYL (793 patients)
VERSED (783 patients)
PREDNISONE (758 patients)
OMEPRAZOLE (756 patients)
PLAVIX (753 patients)
MYCOPHENOLATE MOFETIL (751 patients)
DIOVAN (744 patients)
ACETAMINOPHEN (728 patients)
TACROLIMUS (724 patients)
PLATELETS (722 patients)
ATENOLOL (709 patients)
SIMVASTATIN (707 patients)
DIGOXIN (694 patients)
METFORMIN HCL (648 patients)
METHOTREXATE (633 patients)
PROGRAF (629 patients)
ZOMETA (619 patients)
EXJADE (615 patients)
AMLODIPINE (586 patients)
ZOCOR (575 patients)
COUMADIN (568 patients)
SPIRONOLACTONE (537 patients)
DOPAMINE HCL (532 patients)
MANNITOL (530 patients)
POTASSIUM CHLORIDE (520 patients)
EPINEPHRINE (519 patients)
LANSOPRAZOLE (510 patients)
WARFARIN SODIUM (506 patients)
ENALAPRIL MALEATE (503 patients)
AMIODARONE HCL (494 patients)
TOPROL-XL (491 patients)
HYDROCHLOROTHIAZIDE (490 patients)
REVLIMID (472 patients)
FAMOTIDINE (457 patients)
METOPROLOL TARTRATE (452 patients)
LEVOTHYROXINE SODIUM (450 patients)
FOLIC ACID (438 patients)
ANCEF (436 patients)
ALDACTONE (427 patients)
ALBUMIN (HUMAN) (425 patients)
LANTUS (424 patients)
LIDOCAINE (424 patients)
FRESH FROZEN PLASMA (420 patients)
CYCLOPHOSPHAMIDE (414 patients)
SODIUM BICARBONATE (410 patients)
CRESTOR (405 patients)
REBETOL (389 patients)
SOLU-MEDROL (385 patients)
LOPRESSOR (382 patients)
NEXIUM (369 patients)
RAMIPRIL (369 patients)
PROPOFOL (368 patients)
PREDONINE (364 patients)
VIOXX (355 patients)
CELEBREX (352 patients)
METHYLPREDNISOLONE (348 patients)
SYNTHROID (343 patients)
DEXAMETHASONE (342 patients)
REMICADE (341 patients)
CARVEDILOL (340 patients)
CELLCEPT (340 patients)
HUMIRA (339 patients)
MORPHINE (339 patients)
COREG (334 patients)
HEPARIN SODIUM INJECTION (332 patients)
MILRINONE (332 patients)
LOXONIN (329 patients)
PRADAXA (323 patients)
CISPLATIN (323 patients)
ACYCLOVIR (320 patients)
CLOZARIL (317 patients)
AMARYL (314 patients)
IBUPROFEN (312 patients)
FOSAMAX (312 patients)
TELAVIC (TELAPREVIR) (308 patients)
LEVOPHED (303 patients)
VALTREX (301 patients)
LYRICA (299 patients)
OXYCONTIN (293 patients)
HUMALOG (289 patients)
PROTONIX (286 patients)
PREDNISONE TAB (285 patients)
ACTOS (281 patients)
CALCIUM CHLORIDE (276 patients)
DECADRON (275 patients)
GABAPENTIN (274 patients)
FLUOROURACIL (272 patients)
LOVENOX (272 patients)
MAGNESIUM SULFATE (269 patients)
CERTICAN (267 patients)
COZAAR (266 patients)
SANDIMMUNE (264 patients)
GLEEVEC (262 patients)
METOPROLOL (260 patients)
CEFAZOLIN (257 patients)
VOLTAREN (256 patients)
HEPARIN SODIUM (255 patients)
URSO 250 (253 patients)
GLYBURIDE (252 patients)
RIBAVIRIN (246 patients)
VITAMIN D (244 patients)
LORAZEPAM (243 patients)
CIPROFLOXACIN (241 patients)
PRILOSEC (240 patients)
MAGNESIUM OXIDE (237 patients)
BYETTA (235 patients)
FORTEO (234 patients)
MICARDIS (232 patients)
AVANDIA (230 patients)
NEXAVAR (228 patients)
CONTRAST MEDIA (225 patients)
PLASMA (225 patients)
LEVAQUIN (224 patients)
FLUCONAZOLE (220 patients)
AZATHIOPRINE (220 patients)
DIFLUCAN (219 patients)
PEPCID (218 patients)
XANAX (218 patients)
ALTACE (216 patients)
PEG-INTRON (215 patients)
MIDAZOLAM HCL (215 patients)
LAMIVUDINE (213 patients)
CALCIUM (213 patients)
MUCOSTA (212 patients)
CLARITHROMYCIN (210 patients)
CLONIDINE (209 patients)
ITRACONAZOLE (208 patients)
NEURONTIN (206 patients)
AMLODIPINE BESYLATE (206 patients)
PHENYLEPHRINE HCL (206 patients)
BACTRIM (206 patients)
IMDUR (204 patients)
ALBUTEROL (204 patients)
AVONEX (202 patients)
GLUCOPHAGE (202 patients)
RABEPRAZOLE SODIUM (200 patients)
VELCADE (199 patients)
NIFEDIPINE (199 patients)
NORVIR (198 patients)
ATIVAN (198 patients)
AFINITOR (198 patients)
PREVACID (198 patients)
AMBIEN (196 patients)
AMBISOME (195 patients)
LITHIUM CARBONATE (194 patients)
ZESTRIL (191 patients)
PAXIL (190 patients)
ATORVASTATIN CALCIUM (189 patients)
ADALAT (189 patients)
DOBUTAMINE HCL (189 patients)
AMICAR (188 patients)
ETOPOSIDE (187 patients)
ENBREL (186 patients)
MEROPENEM (186 patients)
AREDIA (185 patients)
ZANTAC (184 patients)
LEVOFLOXACIN (184 patients)
RASILEZ (183 patients)
SUTENT (182 patients)
ISOSORBIDE MONONITRATE (182 patients)
RAPAMUNE (179 patients)
VICODIN (179 patients)
AMOXICILLIN (179 patients)
TAKEPRON (178 patients)
ETOMIDATE (178 patients)
BISOPROLOL FUMARATE (177 patients)
FERROUS SULFATE TAB (177 patients)
GENTAMICIN (176 patients)
LANOXIN (176 patients)
CALCIUM CARBONATE (176 patients)
PAVULON (175 patients)
METFORMIN (174 patients)
ZETIA (173 patients)
METOPROLOL SUCCINATE (172 patients)
LOSARTAN POTASSIUM (172 patients)
CANDESARTAN CILEXETIL (172 patients)
ICL670A ICL+DISTAB (170 patients)
DOXAZOSIN MESYLATE (170 patients)
SULFAMETHOXAZOLE AND TRIMETHOPRIM (169 patients)
ZOFRAN (168 patients)
ZINACEF (164 patients)
SEROQUEL (164 patients)
AVASTIN (163 patients)
PROTAMINE (162 patients)
PEGINTERFERON ALFA-2B (161 patients)
SELBEX (160 patients)
RED BLOOD CELLS, CONCENTRATED (160 patients)
GLIPIZIDE (160 patients)
ZYPREXA (159 patients)
RANITIDINE (159 patients)
CYTARABINE (159 patients)
AMIODARONE (158 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about RENAL IMPAIRMENT and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.